Although it has been hypothesized that ATM mutations are correlated with sensitivity to PARP inhibition, in a recent phase 3 trial, there was no survival benefit seen for patients with prostate cancer associated with ATM mutations who were treated with olaparib vs androgen-receptor targeted therapy (HR, 0.93; 95% CI, 0.53–1.75)59. The gene discussed is AR; the disease is prostate carcinoma.